Thomas A Barta

US Patent:

20220267269, Aug 25, 2022

Filed:

Jun 12, 2020

Appl. No.:

17/618873

Inventors:

- Pittsford NY, US
Mark Karbarz - Burlingame CA, US
Jiang Zhu - Palo Alto CA, US
Thomas E. Barta - Carrboro NC, US
Jonathan William Bourne - Fairport NY, US
Anjali Pandey - Fremont CA, US

International Classification:

C07D 211/42
C07D 207/08
C07D 211/14
C07D 211/18
C07D 211/38
C07D 211/56
C07D 233/10
C07D 233/22
C07D 265/30
C07D 401/04
C07D 401/06
C07D 401/10
C07D 401/14
C07D 405/04
C07D 405/06
C07D 405/14
C07D 413/14
C07D 417/04
C07D 471/04
C07D 471/14
C07D 498/04

Abstract:

The present disclosure relates to novel compounds capable of binding to PCSK9, thereby modulating PCSK9 biological activity. Also provided are compositions comprising these compounds, methods of preparing the compounds, and methods for use of the compounds in the treatment of PCSK9-related conditions and diseases.

US Patent:

20220193058, Jun 23, 2022

Filed:

Dec 16, 2020

Appl. No.:

17/124357

Inventors:

- Pittsford NY, US
Mark Karbarz - Burlingame CA, US
Jiang Zhu - Palo Alto CA, US
Thomas E. Barta - Carrboro NC, US
Jonathan William Bourne - Fairport NY, US
Anjali Pandey - Fremont CA, US

International Classification:

A61K 31/451
C07D 211/14
C07D 401/04
A61P 3/06
A61K 31/4545

Abstract:

The present disclosure relates to novel compounds capable of binding to PCSK9, thereby modulating PCSK9 biological activity. Also provided are compositions comprising these compounds, methods of preparing the compounds, and methods for use of the compounds in the treatment of PCSK9-related conditions and diseases.

US Patent:

20210032214, Feb 4, 2021

Filed:

Apr 28, 2020

Appl. No.:

16/861166

Inventors:

- Pittsford NY, US
Simeon Bowers - Oakland CA, US
Thomas E. Barta - Carrboro NC, US
Jonathan William Bourne - Fairport NY, US

International Classification:

C07D 295/073
C07D 401/04
C07D 403/04
C07D 211/18
C07D 211/26
C07D 211/46
C07D 211/54
C07D 211/58
C07D 295/195
C07D 401/12
C07D 401/14
C07D 405/14
C07D 407/02
C07D 417/04
C07D 417/14
C07D 471/08

Abstract:

The present disclosure relates to novel compounds, methods, and compositions capable of binding to PCSK9, thereby modulating PCSK9 proprotein convertase enzyme activity. The compounds of the disclosure include compounds Formula (I).

US Patent:

20200071308, Mar 5, 2020

Filed:

May 10, 2019

Appl. No.:

16/408959

Inventors:

- Indianapolis IN, US
Jeron Eaves - San Francisco CA, US
Gunnar Hanson - Bothell WA, US
James Veal - Apex NC, US
Thomas Barta - Carrboro NC, US
Lifeng Geng - Midlothian VA, US
Lindsay Hinkley - Lincoln University PA, US

International Classification:

C07D 409/12
A61K 45/06
A61K 31/4439
C07D 413/12
C07D 231/54
A61N 5/10
A61K 45/00
A61K 31/5377
A61K 31/454
A61K 31/416
A61K 31/404
C07D 209/08
C07D 405/12
C07D 403/12
C07D 401/12
C07D 231/56
C07D 209/14

Abstract:

Disclosed are compounds and pharmaceutically acceptable salts of Formula Iwherein R, R, R, R, R, R, R, n, Q, Q, Q, Y, and X-Xare as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

US Patent:

20170260174, Sep 14, 2017

Filed:

May 22, 2017

Appl. No.:

15/601428

Inventors:

- Indianapolis IN, US
Jeron Eaves - San Francisco CA, US
Gunnar Hanson - Bothell WA, US
James Veal - Apex NC, US
Thomas Barta - Carrboro NC, US
Lifeng Geng - Midlothian VA, US
Lindsay Hinkley - Lincoln University PA, US

International Classification:

C07D 409/12
C07D 231/56
C07D 401/12
C07D 209/08
C07D 405/12

Abstract:

Disclosed are compounds and pharmaceutically acceptable salts of Formula Iwherein R, R, R, R, R, R, R, n, Q, Q, Q, Y, and X-Xare as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

US Patent:

20140343037, Nov 20, 2014

Filed:

Aug 4, 2014

Appl. No.:

14/451033

Inventors:

- Indianapolis IN, US
Jeron Eaves - San Francisco CA, US
Gunnar Hanson - Bothell WA, US
James Veal - Apex NC, US
Thomas Barta - Carrboro NC, US
Lifeng Geng - Midlothian VA, US
Lindsay Hinkley - Lincoln University PA, US

International Classification:

C07D 209/08
C07D 405/12
C07D 401/12
A61K 31/4439
A61N 5/10
C07D 231/56
A61K 31/416
C07D 409/12
A61K 31/454
A61K 45/06
A61K 31/404
A61K 31/5377

US Classification:

51421018, 548516, 514412, 548465, 514414, 5462774, 514339, 544144, 5142352, 5483601, 514406, 5462757, 514338, 546201, 514323, 600 1

Abstract:

Disclosed are compounds and pharmaceutically acceptable salts of Formula Iwherein R, R, R, R, R, R, R, n, Q, Q, Q, Y, and X-Xare as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.